Agilent Technologies and BioNanomatrix have entered into a collaboration to develop a new genetic analysis system combining the two companies' technologies
BioNanomatrix, which develops breakthrough nanoscale whole genome imaging and analytic platforms, will apply its innovative nanoscale single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the measurement instrumentation platform for the system.
"This collaboration with Agilent provides us with the opportunity to join forces with a global life sciences leader to accelerate the development of our unique nanoscale whole genome imaging technology," said Michael Boyce-Jacino, chief executive officer of BioNanomatrix.
"We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life-sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing".
BioNanomatrix is developing pioneering technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format.
The company's patented analytic platform based on this technology has the potential to provide rapid, comprehensive and cost-effective ultra-high resolution analyses of DNA.
The two companies intend to collaborate closely in the development of an integrated system and applications.
"BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine," said Nick Roelofs, vice president and general manager of the life sciences unit at Agilent.
"We are committed to continuing our leadership in developing important new technologies and solutions for our customers, and we look forward to collaborating with the BioNanomatrix team to enable these powerful new capabilities to reach the marketplace."
